We know every patient needs individualized care. Boston Scientific is leading the way in supporting short DAPT studies with SYNERGY in a variety of patient populations and DAPT durations. Excellent outcomes in long lesions EVOLVE 48 Trial: Final 2-year Results ...
Talk to a Rep Fill out a quick form and one of our sales representatives will be in touch. Let's Talk Boston Scientific is dedicated to transforming lives through innovative medical solutions that improve the health of patients around the world....
On the other hand, in the United States, the Food and Drug Administration (FDA) has only recently approved the use of Paclitaxel-coated balloons for ISR treatment, with the AGENT balloon (Boston Scientific, USA) being the first to receive such approval. Nevertheless, in Europe, DCBs are ...
Boston Scientific. Introduction Coronary artery bypass graft surgery (CABG) has been the standard of care for revascularisation of patients with complex coronary artery disease since its introduction in 1968.1 When percutaneous coronary intervention (PCI) was introduced in 1977,2 it was thought to ...
Advances in PCI include the use of drug-eluting stents and adjunctive drug therapies, such as abciximab. Glycemic control is an important determinant of outcome after revascularization in diabetic patients, and the impact of tight glycemic control after PCI is currently being investigated in the BARI...
It is well accepted that a comprehensive understanding of the geometric anatomical characteristics of the coronary system will allow for medical devices to be engineered to deliver novel therapies more successfully to a greater variety of cardiac patients....
Other therapies for the prevention of POAF have been studied in small trials, but have not demonstrated clear beneficial effects [76]. These include angiotensin converting enzyme inhibitors (ACEIs) [97], magnesium [85, 98, 99], n-3 polyunsaturated fatty acids [100–108], corticosteroids...
The CASCADE trial is funded through several sources, including a Physicians' Services Incorporated Foundation resident research grant, as well as grants from Boston Scientific Inc. and financial support from the Bristol-Myers Squibb Sanofi Canada Partnership. Boston Scientific will supply the intravascular...
Various treatments for patients with coronary artery disease, such as CABG surgery and interventional therapies, have led to accelerated atherosclerosis. These processes occur within months to years, compared with the decades that it generally takes for native disease to develop. Morphological identifiers...
The last 2 decades have witnessed the introduction of a variety of antiatherosclerotic therapies, most notably the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins). Although statins rank among the most extensively studied therapies in contemporary medicine, the optimal target levels ...